Recent Updates
Recently added Catalysts
NAGE Positive Sentiment Score: 70/100

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

Thursday, July 9, 2026 1 min read
Key Takeaway: Niagen Bioscience's CEO, Rob Fried, is set to participate in a virtual fireside chat on July 15, 2026, hosted by KCSA Strategic Communications. The discussion will focus on the company's newly launched pharmaceutical program targeting rare genetic diseases and aging-related disorders. This event aims to enhance awareness of Niagen's initiatives in the biopharma sector.
Price reaction · baseline $3.37 (2026-07-08 close) · hit pre-market · clean, no other NAGE news in the window
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Rob Fried will discuss a new pharmaceutical program.
  • Focus on rare genetic diseases and aging-related disorders.
  • Engagement with KCSA Strategic Communications highlights company visibility.

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the C

Frequently Asked Questions

When will Rob Fried's virtual fireside chat take place?

The virtual fireside chat will occur on July 15, 2026, at 8 am PDT.

What will Rob Fried discuss during the chat?

He will discuss Niagen's new pharmaceutical program for rare genetic diseases.

Who is hosting the virtual fireside chat?

The chat is hosted by KCSA Strategic Communications.

What is the focus of Niagen Bioscience?

Niagen focuses on NAD+ and the science of healthy aging.

Tags: NAGE Viatris Investor Conferences Healthcare Niagen Bioscience Rob Fried pharmaceutical program aging-related disorders
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$67M liquidity · $0M/mo burn
~165 mo
Minimal dilution risk